About Vascular Therapies

Board of Directors

Vascular Therapies' Board of Directors is comprised of experts from the fields of medicine, medical technology, finance, and life science investing.

Robert Croce

Chairman

Robert Croce joined VT’s Board of Directors following a 36 year career at Johnson & Johnson where he held a series of senior positions, culminating with 12 years as Company Group Chairman. Previously, he was Worldwide Franchise Chairman of Cordis, a Johnson & Johnson company.

Prior to that, he was Worldwide Franchise Chairman for Ethicon Endo-Surgery. Mr. Croce began his career with Johnson & Johnson as a Sales Representative for Ortho Pharmaceuticals, where he was named Vice President of Marketing. In 1985, Mr. Croce moved to McNeil Pharmaceutical as Vice President of Business Development. He later transferred to Ethicon, Inc. as Group Vice President, where he remained until he was named President in 1990. In 1992 he was promoted to Worldwide President, Ethicon Endo-Surgery. Mr. Croce also serves on the Board of Directors of Neotract, MoxiMed, ExploraMed/NC7, Earlens, Svelte Medical, and Guided Delivery Systems.

Mr. Croce received his undergraduate and graduate degrees from Central Missouri University.

‍

John McDermott

Chief Executive Officer

John McDermott joined Vascular Therapies as of January 2019 as Chief Executive Officer. Mr. McDermott has over 30 years of senior executive management, sales, marketing, and finance experience in the vascular industry. From 2008 to 2018 he served as the CEO of Endologix, a company that is a developer of aortic stent grafts. From 2002 to 2007 he served as President of Bard Peripheral Vascular, a division of C.R. Bard, Inc. Mr. McDermott previously served as President of Global Sales for C.R. Bard’s vascular surgery and endovascular businesses.

Prior to that, he served for four years as President of C.R. Bard’s division IMPRA, Inc., where he was responsible for global operations, including sales, marketing, research and development, manufacturing, and finance. From 1990 to 1996, Mr. McDermott served as Chief Financial Officer and later Vice President and Chief Operating Officer of IMPRA, Inc., prior to its acquisition by C.R. Bard.

Mr. McDermott holds a B.S. in Finance from Arizona State University and an M.B.A from Western International University.

Sriram Iyer, MD, FACC, FSCAI

Chief Scientific Officer

Sriram Iyer (“Sri”) founded Vascular Therapies in 2001 to address the clinical problem of surgical anastomotic intimal hyperplasia. He is a physician‑scientist and entrepreneur who conceived and patented the Sirogen product concept. Sri has played a leading role in the scientific, operational, clinical and regulatory evolution of the company.

An interventional cardiologist and vascular medicine specialist with more than 25 years of experience in coronary, peripheral vascular and carotid interventions, he served as the Associate Chairman of the Department of Cardiology and the Director of Peripheral Vascular and Carotid Interventions at Lenox Hill Hospital in New York City. Sri is recognized worldwide for his pioneering work and contributions to angioplasty and stenting for treatment of extra‑cranial carotid artery disease. A gifted teacher, he has mentored and trained several cardiologists, many of whom are now directors and department heads in hospitals in the US and abroad.

His experience as an investigator in several FDA regulated clinical trials has provided a solid understanding of the rigor and the regulatory expectations surrounding product approval. Sri has published extensively and holds several patents including methods for treating failure of hemodialysis vascular accesses and vascular grafts. He is a Fellow of the American College of Cardiology (FACC), a Fellow of the Society for Cardiac Angiography and Interventions (FSCAI) and received his M.B; B.S.; M.D. (General Medicine) and D.M. (Cardiology) degrees from the University of Bombay, India.

Andrew Midler

Andrew Midler founded Savitr Capital LLC in 2008, a privately owned investment company which invests in emerging and innovative technology driven companies. Savitr Capital is currently invested in a portfolio of innovation leaders focused in health care and industrial manufacturing. Mr. Midler currently serves on the board of directors of Druggability Technologies, Glytec Systems, CellMDX, Emerald Bio Agriculture, Ancora Heart, BioIQ, and Vascular Therapies. In the majority of these Savitr is a large shareholder and participates at the Board level.

Previously, Mr. Midler founded Standard Pacific Capital in 1995. The investment management firm launched with $75m of assets and grew to over $5 billion and a team of 100 people by 2005. Mr. Midler managed the firm’s Global Long/Short Equity Fund until 2005, Standard Pacific’s flagship product. He also supervised the firm’s Credit Opportunities, Commodity, Quantitative, and Japan Long/Short Equity strategies. He served as the firm’s CIO and CEO from 1995 until December 2007. In December of 2007, he sold his majority ownership interest in the firm. Prior to founding Standard Pacific, he served as the director of equity portfolio management at CS First Boston, a global institutional money management firm. Previously, he managed a significant portion of the global hedge fund Odyssey Partners. From 1986 through 1993, he worked at Fidelity Investments and his tenure included assignments as portfolio manager of the Fidelity Convertible Securities Fund, Fidelity Equity Income II Fund, and Fidelity Growth & Income Fund. He holds an MBA from Harvard Business School and MA and BA degrees in Political Science from Stanford University.

Daniel M. Ryan

Daniel M. Ryan is Managing Director of Spring Bay Ventures, a single-family office in Ponte Vedra Beach, Florida. Since 2003, Mr. Ryan has managed Spring Bay’s venture portfolio, which consists of a range of early stage privately held businesses, primarily in healthcare. Mr. Ryan is responsible for sourcing and executing investment transactions and then assisting portfolio companies achieve their aims through his board membership engagement.

Prior to Spring Bay, Mr. Ryan served for 14 years in a range of senior executive capacities for Unison Industries, a leading supplier of engineered electro-mechanical components for the aviation industry. Over this period, Unison revenues grew from $10 to $200 million leading to its acquisition by General Electric in 2002.

Mr. Ryan holds a B.S. and M.S. in Mechanical Engineering from Purdue University and a M.B.A. from Duke University. Dan also serves as a board member of The Sontag Foundation, The Brain Tumor Network and The Divine Mercy House.

Gerald Dorros, M.D.

Gerald Dorros, M.D., an interventional cardiologist and cardiovascular interventionist, has been the Medical Director of the William Dorros-Isadore Feuer Interventional Cardiovascular Disease Foundation in Scottsdale, Arizona, and Milwaukee, Wisconsin since 1983. He has also served as Director of Cardiology at the Arizona Heart Hospital and at St. Luke’s Medical Center in Milwaukee. He joined the Arizona Heart Institute Foundation, Phoenix, Arizona in 1997 and served as its President from 1997 to 2000. He was the third U.S. physician to perform coronary angioplasty in the United States (1978), the first cardiologist to perform peripheral vascular interventions (1979), the principal author of the first manuscript detailing the complications associated with PTCA, and a founding member of the National Heart, Lung and Blood Institute’s PTCA Registry. He has had multiple university faculty appointments, has taught and performed live demonstrations of both coronary and peripheral vascular interventions throughout the world, and has authored or co-authored more than 250 peer reviewed journal articles, as well as numerous textbook chapters. Dr. Dorros’ entrepreneurial experience has included involvement with more than 50 medical device companies, including co-founding Arterial Vascular Engineering. (AVE subsequently bought by Medtronic) and Power Medical Interventions, as well as recent Director Positions at BioCardia, Vascular Imaging Corporation, and Windmill Cardiovascular Systems.

Dr. Dorros received a B.S. from Dartmouth College (1964), his Medical Degree from The Albert Einstein College of Medicine of Yeshiva University (1968), was granted honorary Doctor of Science degrees from Yeshiva University (2000), and Colby College (2001).

About
Vascular
Therapies

Management

our Team has extensive experience developing and commercializing new drugs and medical devices

Board of Directors

Vascular Therapies' Board of Directors is comprised of experts from the fields of medicine, medical technology, finance, and life science investing.

Contact

CAUTION: THE SIROLIMUS-ELUTING COLLAGEN IMPLANT (SIROGEN^TM) IS AN INVESTIGATIONAL PRODUCT THAT IS NOT AVAILABLE FOR SALE IN ANY COUNTRY. READ OUR Expanded Access Policy.

About VascularTherapies

Management

our Team has extensive experience developing and commercializing new drugs and medical devices

Board of Directors

Vascular Therapies' Board of Directors is comprised of experts from the fields of medicine, medical technology, finance, and life science investing.

Contact

CAUTION: THE SIROLIMUS-ELUTING COLLAGEN IMPLANT (SIROGENTM) IS AN INVESTIGATIONAL PRODUCT THAT IS NOT AVAILABLE FOR SALE IN ANY COUNTRY. READ OUR Expanded Access Policy.

About
Vascular
Therapies

CAUTION: THE SIROLIMUS-ELUTING COLLAGEN IMPLANT (SIROGEN^TM) IS AN INVESTIGATIONAL PRODUCT THAT IS NOT AVAILABLE FOR SALE IN ANY COUNTRY. READ OUR Expanded Access Policy.